Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Long-term tolterodine reduces incontinence, is well tolerated

Aug. 30, 1999

Ferring's antidiuretic agent F-992 evaluated in healthy volunteers

Aug. 26, 1999

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Aug. 23, 1999

Sanofi-Synthelabo submits MAA for Ditropan XL in the U.K.

Aug. 16, 1999

Leading BPH treatment to be copromoted by Abbott and Boehringer Ingelheim

Aug. 16, 1999

NexMed reports results from multiple-use study of topical alprostadil cream

Aug. 16, 1999

NIH initiates interstitial cystitis trial

Aug. 16, 1999

Phase II testing of Alexion's C5 complement inhibitor also begins in renal diseases

Aug. 12, 1999

FDA puts hold on clinical study of Vasomax

Aug. 12, 1999

BioSpecifics Technologies announces positive preliminary results in Peyronie's disease therapy

Aug. 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...